Full-Year 2012 Targets | ||||
| ($ billions, except per-share amounts) | Net Income(b) | Diluted EPS(b) | ||
| Income/(Expense) | ||||
| Adjusted Income/Diluted EPS(1) Targets | ~$18.3 - $19.1 | ~$2.25 - $2.35 | ||
| Purchase Accounting Impacts of Transactions Completed as of 7/4/10 | (3.8) | (0.47) | ||
| Acquisition-Related Costs | (1.2 – 1.6) | (0.15 – 0.20) | ||
| Reported Net Income Attributable to Pfizer Inc./Diluted EPS Targets | ~$12.9 - $14.1 | ~$1.58 - $1.73 | ||
(a) The current exchange rates assumed in connection with the 2012 financial targets are the mid-July 2010 exchange rates. (b)Given the longer-term nature of these targets, they are subject to greater variability and less certainty as a result of potential material impacts related to foreign exchange fluctuations, macroeconomic activity including inflation, and industry-specific challenges including changes to government healthcare policy, among others. | ||||
